Lei Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lei Liu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Jinli Zhang
Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, China
2 shared publicationsBaoru Hu
Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, China
1 shared publicationChun Feng Li
Department of Internal Medicine, Harbin Medical University Cancer Hospital, Haping Road 150 of Nangang District, Harbin, Heilongjiang Province, 150081, China
1 shared publicationChunbo Zhao
Department of Internal Medicine, Harbin Medical University Cancer Hospital, Haping Road 150 of Nangang District, Harbin, Heilongjiang Province, 150081, China
1 shared publicationDi Wu
Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, China
1 shared publicationFanwei Kong
Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin, China
1 shared publication
Latest Publications
- Open Access
- 4 May 2023
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10
Case report: A combined immunotherapy strategy as a promising therapy for MSI-H colorectal carcinomas with multiple HPD risk factors
Approximately 5% of advanced colorectal carcinomas (CRCs) and 12–15% of early CRCs are microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Nowadays, PD-L1 inhibitors or combined CTLA4 inhibitors are the major strategies for advanced or metastatic MSI-H colorectal cancer, but some people still show drug resistance or progression. Combined immunotherapy has been shown to expand the benefit population in non-small-cell lung carcinoma (NSCLC), hepatocellular carcinoma (HCC), and other tumors while reducing the incidence of hyper-progression disease (HPD). Nevertheless, advanced CRC with MSI-H remains rare. In this article, we describe a case of an elder patient with MSI-H advanced CRC carrying MDM4 amplification and DNMT3A co-mutation who responded to sintilimab plus bevacizumab and chemotherapy as the first-line treatment without obvious immune-related toxicity. Our case provides a new treatment option for MSI-H CRC with multiple risk factors of HPD and highlights the importance of predictive biomarkers in personalized immunotherapy.
- 4 May 2023
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10
Open AccessCase report: A combined immunotherapy strategy as a promising therapy for MSI-H colorectal carcinomas with multiple HPD risk factors
Approximately 5% of advanced colorectal carcinomas (CRCs) and 12–15% of early CRCs are microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors. Nowadays, PD-L1 inhibitors or combined CTLA4 inhibitors are the major strategies for advanced or metastatic MSI-H colorectal cancer, but some people still show drug resistance or progression. Combined immunotherapy has been shown to expand the benefit population in non-small-cell lung carcinoma (NSCLC), hepatocellular carcinoma (HCC), and other tumors while reducing the incidence of hyper-progression disease (HPD). Nevertheless, advanced CRC with MSI-H remains rare. In this article, we describe a case of an elder patient with MSI-H advanced CRC carrying MDM4 amplification and DNMT3A co-mutation who responded to sintilimab plus bevacizumab and chemotherapy as the first-line treatment without obvious immune-related toxicity. Our case provides a new treatment option for MSI-H CRC with multiple risk factors of HPD and highlights the importance of predictive biomarkers in personalized immunotherapy.
- Open Access
- 1 January 2022
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 13 (4) , 1130-1144
Green walnut husk extracts Proliferation and Migration in Gastric Cancer
Background: In the past few decades, natural products have become an increasingly important source of potential anti-cancer agents. The green walnut husk(GWH) extracts have been reported to inhibit multiple tumor cells and might be a promising chemopreventive agent in human neoplasia. However, it is not clear whether GWH extracts inhibit gastric cancer.
- 1 January 2022
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 13 (4) , 1130-1144
Open AccessGreen walnut husk extracts Proliferation and Migration in Gastric Cancer
Background: In the past few decades, natural products have become an increasingly important source of potential anti-cancer agents. The green walnut husk(GWH) extracts have been reported to inhibit multiple tumor cells and might be a promising chemopreventive agent in human neoplasia. However, it is not clear whether GWH extracts inhibit gastric cancer.